Frontlight ResearchEarly access
What researchers published on Mesothelioma
6,202 papers, newest first.
Showing 20 of 187
Trial resultPreclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.Nature communications
In plain wordsRead moreRead the paper on PubMedTrial resultCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma.Clinical lung cancer
Randomised trialGemcitabine as maintenance treatment of diffuse pleural mesothelioma: randomized phase II study.BMC cancer
In plain wordsRead moreRead the paper on PubMedTrial resultPhase 1/1b study of direct intratumoral injection of pleural mesothelioma of immunostimulant prior to surgical resection.The Journal of thoracic and cardiovascular surgery
In plain wordsRead moreRead the paper on PubMedRandomised trialFive-Year Clinical Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Unresectable Pleural Mesothelioma in CheckMate 743.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
In plain wordsRead moreRead the paper on PubMedTrial resultPembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial.Clinical lung cancer
Randomised trialEvaluation of an educational program for nurses on the care coordination of pleural mesothelioma patients: A pilot randomized controlled trial.Japan journal of nursing science : JJNS
In plain wordsRead moreRead the paper on PubMedTrial resultPhase 1 study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers.Molecular therapy : the journal of the American Society of Gene Therapy
In plain wordsRead moreRead the paper on PubMedRandomised trialNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG).Lung cancer (Amsterdam, Netherlands)
In plain wordsRead moreRead the paper on PubMedTrial resultPembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study.The Lancet. Oncology
In plain wordsRead moreRead the paper on PubMedTrial resultFirst-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors.ESMO open
In plain wordsRead moreRead the paper on PubMedTrial resultYAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.Nature medicine
Trial resultPerioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses.Nature medicine
Randomised trialA randomized comparative study on maintenance gemcitabine versus supportive care in pleural mesothelioma.Future oncology (London, England)
Trial resultKEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.Cancer science
Trial resultEfficacy and safety of bintrafusp alfa evaluated in a phase II single-arm clinical trial in previously treated advanced pleural mesothelioma.Lung cancer (Amsterdam, Netherlands)
Trial resultAd-SGE-DKK3 Gene Therapy Overcomes Resistance to Immune Checkpoint Blockade in Pleural Mesothelioma.Clinical cancer research : an official journal of the American Association for Cancer Research
Randomised trialEvaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer.Clinical and translational science
Trial resultWT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome.Journal of hematology & oncology
Randomised trialA randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13-18 BEAT-meso trial.Annals of oncology : official journal of the European Society for Medical Oncology